Figure 1.

Sublethal exposure to ranalexin (iTRAQ). Growth is shown for duplicate samples of MRSA-252 cultured with 20 μgml^-1 ranalexin (▲, Δ) and controls (■, □). Total CFU/ml is shown for ranalexin treated samples (○) and controls (●). Ranalexin treatment produces a temporary reduction of growth rate. Cells were harvested for proteome profiling by iTRAQ (Methods) at OD600 0.58, or one hour after ranalexin addition.